Page 24 - 80_04

M. C. Avendaño López

13. Hensley, L. E.; Stevens, E. L.; Yan, S. B.; Geisbert, J. B.;. Macias, W. L.; Larsen, T.; Daddario-
DiCaprio, K. M.; Cassell, G. H.; Jahrling, P. B.; Geisbert, T. W. Recombinant human activated
protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196,
S390-S399 (2007).

14. Geisbert, T. W.; Hensley, L. E.; Jahrling, P. B.; Larsen, T.; Geisbert, J. B.; Paragas, J.; Young, H.
A.; Fredeking, T. M.; Rote, W. E.; Vlasuk, G. P. Treatment of Ebola virus infection with a
recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362,
1953-1958 (2003).

15. Uzé, G.; Schreiber, G.; Piehler, J.; Pellegrini, S. The receptor of the type I interferon family.
Curr. Top. Microbiol. Immunol. 316, 71-95 (2007).

16. Smith, L. M.; Hensley, L. E.; Geisbert, T. W.; Johnson, J.; Stossel, A.; Honko, A.; Yen, J. Y.;
Geisbert, J.; Paragas, J.; Fritz, E.; Olinger, G.; Young, H. A.; Rubins, K. H.; Karp, C. L.
Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and
Marburg hemorrhagic fever. J. Infect. Dis. 208, 310-318 (2013).

17. Qiu, X.; Wong, G.; Fernando, L.; Audet, J.; Bello, A.; Strong, J.; Alimonti, J. B.; Kobinger, J. P.
MAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates
when administered after the detection of viremia and symptoms, Sci. Transl. Med. 5, 207
ra143 (2013).

18. Geisbert, T. W.; Lee, A. C.; Robbins, M.; Geisbert, J. B.; Honko, A. N.; Sood, V.; Johnson, J. C.; de
Jong, S.; Tavakoli, I.; Judge, A.; Hensley, L. E.; Maclachlan, I. Postexposure protection of non-
human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-
concept study. Lancet, 375, 1896-1905 (2010).

19. Heald, A. E.; Iversen, P. L.; Saoud, J. B.; Sazani, P.; Charleston, J. S.; Axtelle, T.; Wong, M.;
Smith, W. B.; Vutikullird, A.; Kaye, E. Safety and Pharmacokinetic Profiles of
Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and
Marburg Virus: Results of Two Single-Ascending-Dose Studies. Antimicrob. Agents
Chemother, 58, 6639-6647 (2014).

20. (a) Stock, I. Marburg and Ebola hemorrhagic fevers-pathogens, epidemiology and therapy.
Med. Monatsschr. Pharm. 37, 324-330 (2014). (b) Warren, T. K.; Wells, J.; Panchal, R. G.;
Stuthman, K. S.; Garza, N. L.; Van Tongeren, S. A.; Dong, L.; Retterer, C. J.; Eaton, B. P.;
Pegoraro, G.; Honnold, S.; Bantia, S.; Kotian, P.; Chen, X.; Taubenheim, B. R.; Welch, L. S.;
Minning, D. M.; Babu, Y. S.; Sheridan, W. P.; Bavari, S. Protection against filovirus diseases
by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405, (2014).

21. Baranovich, T.; , S.-S.; Armstrong, J.; Marjuki, H.; , R. J.; Webster, R. G.; Govorkova, E. A. T-
705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses in Vitro. J. Virol.
87, 3741-3751 (2013).

22. Kiso, M.; Takahashi, K.; Sakai-Tagawa, Y.; Shinya, K.; Sakabe, S.; Le, Q. M.; Ozawa, M.; Furuta,
Y.; Kawaoka, Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc.
Natl. Acad. Sci. U S A 107, 882-887 (2010).

23. (a) Furuta, Y.; Takahashi, K.; Fukuda, Y.; Kuno, M.; Kamiyama, T.; Kozaki, K.; Nomura, N.;
Egawa, H.; Minami, S.; Watanabe, Y.; Narita, H.; Shiraki, K. In vitro and in vivo activities of
anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46, 977-981
(2002). (b) Para una revisión ver: Furuta, Y.; Gowen, B. B.; Takahashi, K.; Shiraki, K.; Smee,
D. F.; Barnard, D. L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral
Res. 100, 446-454 (2013).

24. Naesens, L.; Guddat, L. W.; Keough, D. T.; van Kuilenburg, A. B.; Meijer, J.; Vande Voorde, J.;
Balzarini, J. Role of human hypoxanthine guanine phosphoribosyltransferase in activation
of the antiviral agent T-705 (favipiravir). Mol. Pharmacol. 84, 615-629 (2013).

25. (a) Smither, S. J.; Eastaugh, L. S.; Steward, J. A.; Nelson, M.; Lenk, R. P.; Lever, M. S. Post-
exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a
mouse model. Antiviral Res. 104, 153-155 (2014). (b) Oestereich, L.; Lüdtke, A.; Wurr, S.;
Rieger, T.; Muñoz-Fontela, C.; Günther, S. Successful treatment of advanced Ebola virus
infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 105, 17-21
(2014).

26. Florescu, D. F.; Keck, M. A. Development of CMX001 (Brincidofovir) for the treatment of
serious diseases or conditions caused by dsDNA virases. Expert Rev. Anti Infect. Ther. 12,
1171-1178 (2014).

27. Johansen, L- M.; Brannan, J. M.; Delos, S. E.; Shoemaker, C. J.; Stossel, A.; Lear, .; Hoffstrom, B.
G.; Dewald, L. E.; Schornberg, K. L.; Scully, C.; Lehar, J.; Hensley, L. E.; White, J. M.; Olinger,

664